Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Table 2

Demographic characteristics of patients and composition of serious adverse events.

Variables	Reports	Percentage
Occupation
Physician	827	37.59%
Pharmacist	47	2.14%
Other health professional	563	25.59%
Lawyer	7	0.32%
Consumer or nonhealth professional	655	29.77%
Unknown	101	4.59%
Gender
Male	1128	51.27%
Female	863	39.23%
Unknown	209	9.50%
Age (y)
<18	22	1.00%
18-44	300	13.64%
45-64	872	39.77%
65-74	157	7.14%
≥75	11	0.50%
Unknown	835	37.95%
Seriousness
Death	143	6.50%
Hospitalization	657	29.86%
Congenital anomalies	4	0.18%
Disabling	74	3.36%
Life threatening	103	4.68%